PPARγ is functionally expressed in clear cell renal cell carcinoma

NICOLAS COLLET, SANDRINE THÉOLEYRE, JULIE RAGEUL, STÉPHANIE MOTTIER, FLORENCE JOUAN, NATHALIE RIOUX-LECLERCQ, PATRICIA FERGELOT, JEAN-JACQUES PATARD, DAMIEN MASSON and MARC G. DENIS

CNRS UMR 6061, Institut de Génétique et Développement, Université Rennes 1, 35043 Rennes, France

Received September 8, 2010; Accepted November 5, 2010

DOI: 10.3892/ijo.2010.891

Abstract. Peroxisome proliferator-activated receptor gamma (PPARγ) agonists have been demonstrated to exert an inhibitory effect on cell growth in several tumor models, including clear cell renal cell carcinoma (CCRCC). PPARγ has therefore been proposed to be a potential therapeutic target. Thus, the PPARγ gene must be expressed and not altered in cancer cells. We have therefore analyzed tumor specimens collected from 63 patients with CCRCC who underwent partial or total nephrectomy. The multiplex ligation-dependent probe amplification (MLPA) assay was used to detect deletions in the PPARγ gene. The majority of the tumors (48/63; 76.2%) did not present alterations. Two samples (3.2%) presented a deletion of the non-coding exon A1. Nine samples (14.3%) showed large heterozygous deletions in chromosome 3p including PPARγ. Potential mutations were analyzed by DNA sequencing of the 6 coding exons of the PPARγ gene. No mutation was found in exons 1-5. In exon 6, a silent polymorphism was detected in 14 samples (22.2%). CCRCC were found to express the PPARγ1 isoform. The expression level of PPARγ was measured by real-time quantitative PCR. A significantly reduced transcript level was associated with an elevated Fuhrman grade. Finally, we analyzed the expression of angiopoietin-like 4, a known PPARγ target gene, in CCRCC cell lines cultured in the presence of rosiglitazone, a known PPARγ agonist. A strong induction was found in the 3 cell lines tested, indicating that PPARγ is functional in all these cell lines. In conclusion, we show here that PPARγ is expressed and functional in CCRCC, prerequisites for being a potential target for CCRCC treatment.

Introduction

Renal cell carcinoma (RCC) accounts for 3% of all solid tumors. It is the sixth leading cause of cancer related deaths due to the lack of effective therapy for locally advanced or metastatic disease (1). Seventy-five percent of RCC are clear cell carcinomas (CCRCC). Important progress in the biology of these tumors has been made. In particular, the loss of function of the von Hippel-Lindau (VHL) tumor suppressor gene is involved in ~70% of sporadic CCRCCs. The biallelic disruption of the VHL gene leads to dysregulation of target genes, such as the vascular endothelial growth factor (VEGF), a central mediator of tumor angiogenesis. Consequently, significant progresses have been made in the medical treatment of metastatic RCC by targeting a number of growth factors, including VEGF, platelet-derived growth factor (PDGF) and their receptors (2,3). Indeed, median progression-free survival time has been doubled either in first line or in second line therapy by targeting tumor angiogenesis (4).

Peroxisome proliferator-activated receptor gamma (PPARγ) is a member of the nuclear receptor superfamily of ligand-activated transcriptional factors (5). PPARγ is expressed in a variety of normal tissues where it plays an important role in metabolic diseases, and cancer (6-8). PPARγ is also highly expressed in many tumors and cancer cell lines derived, for instance, from colon (9), breast (10), lung (11), thyroid (12) and gastric (13) tumors. PPARγ agonists have been extensively investigated as potential anti-tumor drugs, and they have been shown to inhibit growth of malignant human cells, and cause cell cycle arrest and apoptosis in a broad spectrum of epithelial derived tumor cell lines in vitro (14,15). In vivo, synthetic PPARγ agonists, such as the thiazolidinediones decrease the development of tumors in xenograft models (9,16,17). PPARγ ligands also induce cell cycle arrest and apoptosis in human CCRCC cell lines (18-20), and reduce the production of potent angiogenic factors such as VEGF and FGF (18). These observations demonstrate that PPARγ agonists are inhibitors of angiogenesis and altogether, these data suggest that PPARγ ligands agonists may have promise in CCRCC treatment.

The PPARγ gene is located on chromosome 3 (3p25) (21), close to the VHL (von Hippel-Lindau) tumor suppressor gene located in band 3p25-26 (22). The VHL gene is frequently deleted in CCRCC (23-25), and therefore we performed allelic
quantification using MLPA to determine whether the PPARγ gene was also deleted. We also sequenced all the common coding exons of PPARγ, and then tested PPARγ expression in CCRCC by RT-PCR and immunoblotting. Finally, we treated CCRCC cell-lines with a PPARγ agonist to induce the expression of target genes. We show here that PPARγ is expressed and functional in CCRCC, prerequisites for being a potential target for CCRCC treatment.

Materials and methods

Tumor specimens. A total of 63 patients operated for a sporadic CCRCC in the Department of Urology at the Rennes University Hospital between 2003 and 2005 were analyzed. The study protocol was approved by the institutional ethics committee and informed consent for participating in this study was obtained in each case. The following variables were prospectively noted: age, gender, TNM stage, ECOG performance status.

Macroscopic and histologic parameters analyzed included tumor size, tumor necrosis and nuclear Fuhrman grade (26,27). Tumor stage was defined according to the pTNM classification (28,29).

Tumors from untreated patients undergoing partial or total nephrectomy were analyzed. Immediately after macroscopic examination, small tumor non-necrotic sample were collected from surgical specimens, frozen in liquid nitrogen and stored at -80°C.

Multiplex ligation-dependent probe amplification (MLPA). DNA was extracted from snap-frozen tumors using the iPrep gDNA Tissue kit (Invitrogen, Carlsbad, CA, USA), after histological control. The multiplex ligation-dependent probe amplification (MLPA) method was used to establish the copy number of several nucleic acid sequences in a semi-quantitative manner (30).

MLPA was performed using the SALSA MLPA P224 kit (MRC-Holland, Amsterdam, The Netherlands). Details on probe sequences, gene loci and chromosome locations can be found at www.mlpa.com. This assay allows to detect deletions or duplications in the probe sequences, gene loci and chromosome locations can be found at www.mlpa.com. The cut-off level for relative loss of copy number was set at r=0.8.

DNA sequencing. The six common PPARγ (NM_138711) coding exons have been analyzed. The primers used will be given on demand. PCR clean-up was performed using ExoSAP® (USB Corp., Cleveland, OH). Sequencing was performed using standard procedures with the BigDye® Terminator v3.1 kit (Applied Biosystems). The CodonCode Aligner software (CodonCode Corp., Dedham, MA) was used for sequencing analysis.

RNA extraction, cDNA synthesis and qualitative RT-PCR. Total RNA was extracted from snap-frozen tumors using the QIAamp total RNA kit (Qiagen, Hilden, Germany) after histological control. Integrity of RNA samples was controlled by analysis on Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). Following analysis, an RNA integrity number (RIN) was calculated. Only RNA with a RIN >8 were further processed and used for cDNA synthesis as previously described (32).

The relative expression of human PPARγ variants was studied by RT-PCR, using oligonucleotides which allowed us to distinguish between PPARγ1 and γ2 mRNA (Fig. 2A). The sequence of these primers are available upon request. PCR amplifications were performed using the LC480 SYBR Green I Master mix (Roche Diagnostics, Meylan, France) in a Rotorgene 3000 instrument (Corbett Research, BioLabo, Archamps, France). The reaction mixture contained 10 µl of the supplied 2x mix, 0.5 µl of each primer (final concentration 0.25 µM each), 9 µl of the template (cDNA diluted 1/40). The cycling conditions were as follows: denaturation for 5 min at 95°C; amplification for 35 cycles, with denaturation for 5 sec at 95°C, annealing for 5 sec at 63°C and extension for 5 sec at 72°C. Amplicons were then analyzed by gel electrophoresis on 10% polyacrylamide gels (Invitrogen).

Quantitative RT-PCR. Real-time PCR was performed according to previous reports (33). Primers were designed from the sequence of the human cDNAs using the Universal ProbeLibrary Assay Design Center (https://www.roche-applied-science.com/sis/rtpcr/upl). They were selected for binding to separate exons to avoid false-positive results arising from amplification of contaminating genomic DNA. We verified that all amplifications did not yield any product when reverse transcriptase was omitted in the cDNA synthesis reaction. The sequences of these primers are available upon request. PCR amplifications were performed as described above. The cycling conditions were as follows: denaturation for 5 min at 95°C; amplification for 35 cycles, with denaturation for 5 sec at 95°C, annealing for 5 sec and extension for 5 sec at 72°C. To exclude primer-dimer artifacts, fluorescence was not measured at the end of the extension step, but a separate detection step was added (10 sec) at a temperature above the melting point of primer-dimers and below the melting point of the specific PCR product. A standard curve was generated with serial dilutions of pooled cDNAs samples. The amount of transcripts was calculated from these standard curves using theRotorGene software. For each sample, the ratio between the relative amount of each specific transcript and ß-actin was then calculated to compensate for variations in quantity or quality of starting mRNA as well as for differences in reverse transcriptase efficiency.
Table I. Clinicopathologic characteristics of the 63 CCRCC patients.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Number (Percent)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>63.8 (21-83)</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>36 (57.1%)</td>
</tr>
<tr>
<td>Female</td>
<td>27 (42.9%)</td>
</tr>
<tr>
<td>Fuhrman grade</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>1 (1.6%)</td>
</tr>
<tr>
<td>2</td>
<td>21 (33.3%)</td>
</tr>
<tr>
<td>3</td>
<td>24 (38.1%)</td>
</tr>
<tr>
<td>4</td>
<td>17 (27.0%)</td>
</tr>
<tr>
<td>Tumor stage</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>20 (31.7%)</td>
</tr>
<tr>
<td>2</td>
<td>11 (17.5%)</td>
</tr>
<tr>
<td>3</td>
<td>29 (46.0%)</td>
</tr>
<tr>
<td>4</td>
<td>3 (4.8%)</td>
</tr>
<tr>
<td>Lymph node status</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>50 (79.3%)</td>
</tr>
<tr>
<td>1 or 2 (+)</td>
<td>13 (20.7%)</td>
</tr>
<tr>
<td>Metastasis status</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>40 (63.5%)</td>
</tr>
<tr>
<td>+</td>
<td>23 (36.5%)</td>
</tr>
</tbody>
</table>

Values are presented as median (minimum-maximum) for continuous variables and number of patients (percent) for categorical variables.

**Results**

We analyzed tumors obtained from 63 patients with CCRCC who underwent partial or total nephrectomy between 2003 and 2005. The main clinical features are presented on Table I.

**MLPA.** CCRCC frequently present deletion of the VHL gene (23,25). In our cohort, 70% of the patient samples were previously shown to present deletions of the VHL gene as determined by MLPA (24). As PPARγ is located in closed proximity to VHL, on band 3p25 (21), we first performed PPARγ MLPA analysis using a specifically designed assay to assess a potential allelic loss. Fig. 1A presents the results obtained with DNA extracted from normal kidney as a control. The 63 tumor samples were analyzed. Forty-eight samples (76.2%) presented a normal pattern without any deletion (Fig. 1B). Nine samples (14.3%) showed large heterozygous deletions in chromosome 3p (Fig. 1C). Two samples (3.2%) presented a deletion of the non-coding exon A1: one was homozygous (r=0.22) and the other one was heterozygous (r=0.6). Finally, 4 tumors (6.3%) presented deletions of XPC: one was homozygous (r=0.24) and the other 3 were heterozygous (mean r=0.37). In conclusion, a limited number of tumors (14.3%) presented a deletion of the PPARγ gene, and this was always heterozygous.

**DNA sequencing.** Point mutations of the PPARγ gene have been described in solid tumors (34,35), but RCC have not yet been tested. In order to determine whether the PPARγ gene was mutated in these tumors, we sequenced the six PPARγ coding exons in our series of tumors. No mutation was found in exons 1-5. In exon 6, we identified a previously described polymorphism (rs3856806) in 14 samples (22.2%). One was homozygous (1.6%) and 13 were heterozygous (20.6%). This polymorphism does not affect the amino acid sequence of the PPARγ protein.

**Qualitative RT-PCR.** The human PPARγ gene has nine exons and alternate splicing generates 2 main transcripts, the PPARγ1 and PPARγ2 mRNAs, which differ at their 5'-ends. The 5'-untranslated sequence of PPARγ1 is comprised of exons A1 and A2, whereas that of PPARγ2 plus the additional PPARγ2-specific N-terminal amino acids are encoded by exon B (31). We designed specific primers to selectively amplify PPARγ1 or PPARγ2 (Fig. 2A). In normal human kidney, CCRCC tumors and cell lines, PPARγ1 was expressed (Fig. 2B). In contrast, PPARγ2 was only detected in adipose tissue, used as a positive control.

**Quantitative RT-PCR.** The PPARγ gene has previously been shown to be expressed in CCRCC (36,37). In an initial experiment, we compared PPARγ expression in a series of 20 CCRCC for which RNA extracted from the normal corresponding kidney was of good quality. We did not find any significant difference in PPARγ expression between normal and tumor tissues (data not shown). Similarly, immunohistochemistry did not allow us to demonstrate significant difference between CCRCC and normal kidney (unpublished data). We then assessed PPARγ expression in our 63 tumor
samples. All the tumors tested expressed PPARγ at the transcriptional level. Nevertheless, some differences appeared between tumors with different Fuhrman grades. Grade 4 tumors expressed significantly less PPARγ than the other grades (p<0.05). We also observed differences when comparing T3-T4 tumors and T1-T2 tumors, but the statistical analysis revealed that PPARγ expression did not correlate with the metastasis status (Fig. 3). Tumors presenting an allelic loss did not show a decreased PPARγ expression (not shown).

Western blot analysis. We analyzed PPARγ expression at the protein level in 23 tumor samples. All the samples tested showed a specific expression of PPARγ. We then compared the normalized intensity between two groups of tumors: 8 high grade (Fuhrman 4) and 15 lower grade (Fuhrman grades 1, 2 or 3). Intensity in the F4 group was not statistically different from the F(1+2+3) group of tumors (Fig. 4).

Cell line induction. Three CCRCC cell lines were treated with 10 μM rosiglitazone for 24 h. Expression of ANGPTL4, a known PPARγ target, was measured by real-time quantitative

Figure 1. MLPA analysis of the PPARγ gene in CCRCC. The 9 PPARγ exons are represented on the left (A1-6) and the control probes on the right of the graph. Representative results from 3 types of samples are presented: a normal kidney (A), a tumor with no PPARγ deletion (B), and a sample presenting a large deletion in chromosome 3p (C). For each sample and probe is presented the ratio of the results obtained with tumor DNA and a control DNA. The cut-off threshold (ratio r=0.8) is indicated by an horizontal lane on each graph.

Figure 2. Qualitative RT-PCR analysis of PPARγ in CCRCC. (A) Schematic representation of the PPARγ1 and γ2 transcripts. The specific primers are located on exons A2 and B, respectively. PCR were performed with a common anti-sense primer (exon 1). (B) Representative polyacrylamide gel electrophoresis showing expression of the different PPARγ transcripts in a CCRCC (1), normal kidney (2), adipose tissue (3), and the CCRCC 786-O cell-line (4). The size of both transcripts are presented on the right (PPARγ1, 166 bp; PPARγ2, 224 bp).
RT-PCR. PPAR activation was found to induce ANGPTL4 expression in all cell lines, which induction ratios ranging from 3- (RCC4 cells) to 14-fold for the 786-O cells (Fig. 5). Significant effects were also noted when cells were treated with the natural PPAR ligand, 15-deoxy-Δ12,14-prostaglandin J2 (not shown). Finally, SNAT4, a transporter of neutral amino acid of the solute carrier family (SLC38A4), which is also a PPAR target (unpublished data), was also induced in these experiments (data not shown).

Discussion

Following binding of a natural agonist (e.g., 15-deoxy-Δ12,14-prostaglandin J2) or of a synthetic ligand (e.g., glitazones), PPAR binds to the promoter region of target genes, and modulate their expression. Some of these ligands (rosiglitazone and pioglitazone) have been shown to enhance insulin sensitivity and to stimulate adipogenesis, and are therefore being used for the treatment of type II diabetes (38). Numerous reports have also highlighted the implication of PPAR in cancer. In particular, effects of PPAR agonists on tumor cell proliferation and on angiogenesis have been...
reported (15,39,40). However, very few studies have been carried out on CCRCC, the major form of kidney cancer. In these *in vitro* studies, PPARγ agonists have also been shown to inhibit cell growth, to induce apoptosis of cancer cells, and finally to reduce the production of potent angiogenic factors such as VEGRF and FGF (18-20). These results suggest that PPARγ agonists are potent inhibitors of angiogenesis and that PPARγ may be an interesting target for the treatment of advanced CCRCC.

An important prerequisite for PPARγ agonists to be used as anti-cancer agents is that PPARγ must be expressed and functional in cancer cells. Several reports have described the analysis of the PPARγ gene in tumors. Such alterations turned out to be very rare events (34,35,41,42). In our series of CCRCC, we only found a known polymorphism in 22.2% of the tumors. Interestingly, this polymorphism (rs3856806) does not modify the protein sequence. Beside this polymorphism, we did not find any mutation in our series of CCRCC, which is in agreement with published data obtained with other tumor types.

In contrast, MLPA analysis allowed us to detect tumors presenting large heterozygous deletions on chromosome 3p. This region harbors several tumor suppressor genes such as *VHL, FHIT, RASSF-1* or genes involved in DNA repair such as *MLH-1* (43,44). Most of the CCRCC tumors of our collection (70%) were deleted for *VHL* and 57% showed large deletions on chromosome 3p (data not shown). All the tumors deleted for *PPARγ* (14.3% of our collection) were also deleted for *VHL*. But these tumors did not present a lower PPARγ expression level as determined by RT-PCR.

All the CCRCC tumors tested were found to express PPARγ as determined by RT-PCR and immunoblotting. Our results are in accordance with the report of Yang *et al* who presented a PPARγ expression at both mRNA and protein level in CCRCC tissues (19). We show here for the first time that the PPARγ1 isoform is expressed in these tissues. High grade tumors were found to present lower transcript levels, but immunoblotting experiments did not confirm this difference. Therefore, on this basis, it is tempting to speculate that PPARγ ligand might be effective in the treatment of CCRCC, independently of the Fuhrman grade of the tumor.

Finally, we show that in CCRCC cell lines, PPARγ activation by a synthetic ligand regulates target genes. One of them is ANGPTL4, a protein involved in angiogenesis pathway (45). We also found that SNAT4, a PPARγ target gene identified in colon cancer (unpublished data) was found to be regulated in all 3 CCRCC cell lines tested. Finally, in an effort to identify other PPARγ gene targets in CCRCC, we utilized DNA-microarray technology. The 786-O cell line was cultured for 24 h in the presence or in the absence of a PPARγ agonist (15-deoxy ∆

**References**


